Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 2 | 0 | 0 | 0 | 0 |
Analyst Firms Making Recommendations1
- EF Hutton
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Pasithea Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 07/10/2023 | KTTA | Buy Now | Pasithea Therapeutics | $0.30 | 566.44% | EF Hutton | Elemer Piros | → $2 | Reiterates | Buy → Buy | Get Alert |
| 06/01/2023 | KTTA | Buy Now | Pasithea Therapeutics | $0.30 | 566.44% | EF Hutton | Elemer Piros | → $2 | Assumes | → Buy | Get Alert |
| 04/03/2023 | KTTA | Buy Now | Pasithea Therapeutics | $0.30 | 566.44% | EF Hutton | Constantine Davides | $2.3 → $2 | Maintains | Buy | Get Alert |
| 12/14/2021 | KTTA | Buy Now | Pasithea Therapeutics | $0.30 | 982.97% | EF Hutton | Constantine Davides | — | Initiates | → Buy | Get Alert |
What is the target price for Pasithea Therapeutics (KTTA)?
The latest price target for Pasithea Therapeutics (NASDAQ: KTTA) was reported by EF Hutton on July 10, 2023. The analyst firm set a price target for $2.00 expecting KTTA to rise to within 12 months (a possible 525.20% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pasithea Therapeutics (KTTA)?
The latest analyst rating for Pasithea Therapeutics (NASDAQ: KTTA) was provided by EF Hutton, and Pasithea Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Pasithea Therapeutics (KTTA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pasithea Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pasithea Therapeutics was filed on July 10, 2023 so you should expect the next rating to be made available sometime around July 10, 2024.
Is the Analyst Rating Pasithea Therapeutics (KTTA) correct?
While ratings are subjective and will change, the latest Pasithea Therapeutics (KTTA) rating was a reiterated with a price target of $0.00 to $2.00. The current price Pasithea Therapeutics (KTTA) is trading at is $0.32, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.